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PHeart Rhythm Disorders
Indeterminate” Microvolt T-Wave
lternans Tests Predict High Risk of
eath or Sustained Ventricular Arrhythmias
n Patients With Left Ventricular Dysfunction
lizabeth S. Kaufman, MD, FACC,* Daniel M. Bloomfield, MD, FACC,† Richard C. Steinman, AB,†
earila B. Namerow, PHD,† Ottorino Costantini, MD,* Richard J. Cohen, MD, PHD,‡
. Thomas Bigger, JR, MD†
leveland, Ohio; New York, New York; and Cambridge, Massachusetts
OBJECTIVES This study tested the hypothesis that an “indeterminate” microvolt T-wave alternans
(MTWA) test, when due to ectopy, unsustained MTWA, or low exercise heart rate (HR),
has prognostic significance similar to a positive MTWA test.
BACKGROUND MTWA testing, used to stratify risk of sudden or total mortality in patients with structural
heart disease, has been limited by a substantial number of “indeterminate” tests. Indetermi-
nate tests are due to patient factors—excessive ventricular ectopy during exercise, unsustained
MTWA, or failure to achieve a HR of 105 beats/min for 1 min—or technical factors such
as a noisy recording or an exercise protocol that causes an excessively rapid rise in HR.
METHODS Patients in sinus rhythm with left ventricular ejection fraction 0.40 underwent MTWA
exercise tests, analyzed with the spectral method and classified by a computerized interpre-
tation algorithm. The primary end point was all-cause mortality or documented non-fatal
sustained ventricular arrhythmia (SVA). “Indeterminate” tests were reviewed jointly by 2
readers blinded to subsequent events to determine the primary reason for indeterminacy.
RESULTS Participants (N  549) were 56  13 years and 71% male; 49% had ischemic cardiomyop-
athy. There were 40 deaths and 11 non-fatal SVA. Most (94%) indeterminate results were
due to patient factors. The 2-year rate for death or SVA was 17.8% in patients with an
“indeterminate” MTWA test compared with 12.3% in those with a positive test.
CONCLUSIONS In patients with left ventricular dysfunction, an “indeterminate” MTWA test due to patient
factors predicted death or SVA at least as well as a positive test. (J Am Coll Cardiol 2006;
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.06.04448:1399–404) © 2006 by the American College of Cardiology Foundation
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cicrovolt T-wave alternans (MTWA) was originally rec-
gnized as a tool for identifying which patients with
tructural heart disease should be referred for electrophysi-
logic studies or treated to prevent life-threatening ventric-
lar arrhythmias (1,2). After MADIT (Multicenter Auto-
atic Defibrillator Implantation Trial)-II study reported
hat implantation of an implantable cardioverter-
efibrillator (ICD) improved survival in patients with a
rior myocardial infarction (MI) and advanced left ventric-
lar dysfunction (3), a new goal emerged: to identify, within
atient groups that are considered candidates for ICD
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ew York; and ‡Massachusetts Institute of Technology, Cambridge, Massachusetts.
upported by grants HL-64862 from the National Heart, Lung, and Blood Institute,
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enters Program, National Institutes of Health, Bethesda, Maryland; a grant from
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ambridge Heart and is a consultant to Medtronic. His role in the study was limited
o serving as an expert reader of blinded data.M
Manuscript received January 5, 2006; revised manuscript received May 30, 2006,
ccepted June 5, 2006.herapy, a low-risk subgroup that is unlikely to benefit (4).
ubsequently, several studies showed that MTWA tests
ave high negative predictive accuracy, (i.e., identify a
ubgroup with low risk of death that is therefore unlikely to
enefit from ICD prophylaxis) (5–7). With this negative
redictive approach, patients with nonnegative (i.e., abnor-
al) MTWA tests are all considered suitable for ICD
rophylaxis (1,5–7).
The MTWA tests are classified as negative, positive, or
ndeterminate (8). About 20% to 40% of MTWA tests are
ndeterminate, owing either to patient factors (e.g., frequent
entricular ectopy during exercise) or technical factors (e.g.,
noisy electrocardiogram) (see Methods) (2,9–13). An
arly study of patients with recent MI showed that an
ndeterminate MTWA test was a strong predictor of cardiac
eath (14), but this has not been a consistent finding. A
ecent review of the MTWA literature concluded that the
rognostic significance of indeterminate MTWA tests was
n unsettled issue (15).
We conducted this analysis to quantify the causes of
ndeterminate MTWA tests and their prognostic signifi-
ance. We thought that different causes of indeterminateTWA tests might not only have different frequencies
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Indeterminate T-Wave Alternans Test October 3, 2006:1399–404rom study to study but also have substantially different
ortality rates. We hypothesized that an indeterminate
TWA test due to the patient factors would have similar
rognostic significance to a positive MTWA result. Further,
e predicted that indeterminate MTWA due to technical
actors would not pose a substantial risk.
ETHODS
atient selection. The T-Wave Alternans in Congestive
eart Failure Study was conducted at 11 clinical centers in
he U.S. and has been described previously (5,7). The
nstitutional review board at each clinical center approved
he protocol, and written, informed consent was obtained
rom all patients before their enrollment. Patients were
ligible if they were 18 years or older, had left ventricular
jection fraction (LVEF) 0.40, stable sinus rhythm, and
ere able to exercise on a treadmill or bicycle. Exclusions
ncluded unstable angina, class IV heart failure, atrial
brillation, or prior sustained ventricular arrhythmia (SVA).
he current analysis was prespecified in the original Na-
ional Institutes of Health grant proposal.
ollow-up. Follow-up was conducted 1 month after the
TWA test and every 4 months thereafter. During
ollow-up visits, data were collected on patients’ interim
edical and cardiovascular drug histories.
TWA testing. Patients underwent MTWA testing dur-
ng light bicycle or treadmill exercise while receiving their
sual medications, including beta blocker therapy. Careful
kin preparation and high-resolution electrodes (High-Res,
ambridge Heart, Inc., Bedford, Massachusetts) were used
o reduce noise. The MTWA tests were performed during
heart rate (HR)-based exercise protocol and recorded on
H2000 or Heartwave Systems (Cambridge Heart, Inc.).
esults were classified as positive, negative, or indetermi-
ate by a computerized interpretation algorithm (Version
10, Cambridge Heart, Inc.).
The MTWA tests were classified as positive if there was
1 min of MTWA with an onset at a HR 110 beats/min
hat sustained as long as HR remained above the patient-
pecific onset HR. A test was classified negative if sustained
TWA was not present at an onset HR 110 beats/min
nd if there was 1 min at HR 105 beats/min in sinus
hythm with noise level 2 V and ectopy 10%. Other-
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ARB  angiotensin receptor blocker
CI  confidence interval
HR  heart rate
ICD  implantable cardioverter-defibrillator
LVEF  left ventricular ejection fraction
MI  myocardial infarction
MTWA  microvolt T-wave alternans
SVA  sustained ventricular arrhythmiaise, a test was classified as indeterminate (8). On the basis tf these definitions, an indeterminate MTWA test may be
aused by patient factors or technical factors. Patient factors
nclude: 1) failure to maintain HR between 105 and 110
eats/min for 1 min, 2) unsustained MTWA, or 3)
xcessive ectopy during exercise. Technical factors include:
) a noisy recording, or 2) a rapid rise in HR through the
arget exercise HR range of 105 to 110 beats/min (8). The
umber of technically indeterminate tests can be reduced by
mmediately repeating the test (12,16).
Tests that were classified as “indeterminate” by the
omputerized algorithm were subsequently reviewed jointly
y 2 expert readers blinded to patients’ history and subse-
uent clinical events to determine the primary reason for
ndeterminate MTWA tests. They discussed each indeter-
inate case to reach a consensus.
nd points. As specified in the protocol (7), end points
ere adjudicated by an independent, external events com-
ittee that was unaware of the MTWA test results and that
sed the modified Hinkle-Thaler classification (17) for
ause of death used in MUSST (Multicenter Unsustained
achycardia Trial) (18). The events committee reviewed the
rimary end point case report forms and source documents,
hich included a narrative of the event and other pertinent
ata. The primary end point used in this study included
ll-cause mortality and documented non-fatal SVA (includ-
ng ICD shocks with intracardiac electrograms document-
ng rapid ventricular tachycardia or ventricular fibrillation).
tatistical analysis. Follow-up data were censored on the
ate of heart transplantation or last follow-up. The time
ourse of the primary end point, stratified by MTWA result,
as estimated by the Kaplan-Meier method. The associa-
ion between MTWA and primary end point was assessed
ith Kaplan-Meier product-limit estimates of the survival
unctions and tested with a log-rank test (19). The 24-
onth event rate, estimated by the Kaplan-Meier method,
as used to describe the outcome of patients classified by
TWA, and Cox proportional hazards regression was used
o estimate the hazard ratio and 95% confidence intervals
CIs) (20).
ESULTS
he baseline characteristics of the 549 participants, broken
own by MTWA test result, are listed in Table 1. Overall,
heir mean age was 56  13 years; 71% were men, 49% had
schemic cardiomyopathy, and 51% had nonischemic car-
iomyopathy. Two-thirds of the participants were in New
ork Heart Association functional class II or III, and the
ean ejection fraction was 0.25. About 80% of the partic-
pants were receiving beta blockers. The p values in Table 1
efer to the comparison of patients with positive versus
ndeterminate MTWA results. Compared with patients
ith positive MTWA results, patients with indeterminate
esults were older, had higher LVEF, and were more likely
o have ischemic cardiomyopathy and a prolonged QRS
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October 3, 2006:1399–404 Indeterminate T-Wave Alternans Testuration. Fewer had a history of hospital stays for congestive
eart failure or treatment with digoxin.
During the review of 198 MTWA tests classified as
indeterminate” by the automated reader (7), data from a
epeat test were found for 7 participants. On the basis of the
utomated reading of this second test, 7 participants were
igure 1. Kaplan-Meier estimates of death or non-fatal sustained ventric-
lar arrhythmia comparing patients with negative, positive, and indeter-
inate microvolt T-wave alternans (MTWA) results. The 2-year event
ates were (bottom to top): negative 2.4%, positive 12.3%, and indeter-
Table 1. Baseline Characteristics for Patients W
Microvolt T-Wave Alternans (n  549)
Characteristic
Nega
(n 
Age, yrs 53 
Male 63
White race 54
Ischemic cardiomyopathy 50
Hypertension 45
Current smoker 14
Diabetes mellitus 29
Previous myocardial infarction 45
CABG surgery before enrollment 25
Previous admission for CHF 53
New York Heart Association CHF class
No prior CHF or class I 37
Class II 45
Class III 18
LVEF 0.26 
QRS duration 120 ms 21
Drugs at enrollment
Beta-blocker 88
ACE inhibitor/ARB 86
Diuretic 68
Digoxin 41
Anti-lipid 55
Age and left ventricular ejection fraction (LVEF) are mean
indeterminate microvolt T-wave alternans test.
ACE  angiotensin-converting enzyme; ARB  angio
CHF  congestive heart failure.inate 17.8%. There was no significant difference between the positive and
ndeterminate curves (log-rank test).
f
Heclassified—6 as “negative” and 1 as “positive”—leaving
91 participants in the indeterminate category. Of the 191
articipants with an indeterminate result, there was insuf-
cient information to determine the cause of indeterminacy
n 4 cases. Consequently, all analyses of causes of indeter-
inacy were performed on the remaining 187 participants.
There were 51 primary outcome events (40 deaths and 11
on-fatal SVA) during 2 years of follow-up (mean
ollow-up 20  6 months). The 2-year product-limit event
ates for the primary end point, all-cause mortality or
on-fatal SVA, in participants with negative, positive, or
ndeterminate MTWA tests, were 2.4%, 12.3%, and 17.8%,
espectively (Fig. 1). Figure 2 illustrates the distribution of
igure 2. Causes of indeterminate microvolt T-wave alternans (MTWA)
ests. Only 6.4% of the indeterminate MTWA results were due to technical
Negative, Positive, and Indeterminate
icrovolt T-Wave Alternans
p Value*
Positive
(n  163)
Indeterminate
(n  191)
55  12 60  12 0.001
79 73 0.21
45 58 0.02
40 54 0.01
59 58 0.90
14 8 0.08
28 32 0.35
41 47 0.23
23 34 0.35
68 53 0.01
33 35 0.47
45 40
22 26
0.23  0.08 0.27  0.08 0.0001
26 37 0.05
80 76 0.34
88 86 0.64
78 70 0.12
60 50 0.06
42 49 0.23
. All other values are %. *p values refer to positive versus
receptor blocker; CABG  coronary artery bypass graft;ith
M
tive
195)
13
0.09
 SDactors; the remainder were due to patient factors. BPM  beats/min;
R  heart rate.
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Indeterminate T-Wave Alternans Test October 3, 2006:1399–404he causes of indeterminate MTWA tests: HR 105
eats/min in 96 participants, ventricular ectopy in 60,
nsustained MTWA in 19 (i.e., patient factors), and noise
r too-rapid rise in HR in 12 (technical factors). Figure 3
hows Kaplan-Meier plots illustrating the accrual of events
mortality or non-fatal SVA) for each cause of indetermi-
ate MTWA tests. In participants with an indeterminate
TWA test due to patient factors—HR 105 beats/min,
entricular ectopy, or unsustained MTWA—the event rate
xceeded that in the group of patients with a positive test.
one of the patients with an indeterminate MTWA test
ue to technical factors had a primary end point during 2
ears of follow-up.
With a Cox model to compare indeterminate MTWA
ests with positive tests, the hazard ratio was 1.3 (95% CI
.9 to 1.7). Comparing MTWA tests classified as indeter-
inate owing to patient factors with positive tests, hazard
atios ranged from 1.1 to 1.6. These results demonstrate
hat indeterminate MTWA tests predict the primary end
oint as well as positive tests.
Sixty-nine patients had an ICD implanted during 2 years
f follow-up: in 13% of patients with a negative test, 13% of
hose with a positive test, and 12% of those with an
ndeterminate test. Eleven patients had a non-fatal SVA as
heir end point. All 11 patients had ICDs, and these events
ere adjudicated by reviewing electrograms associated with
CD shocks. Among these 11 patients, 2 had negative
TWA tests, 5 had positive tests, and 4 had indeterminate
ests.
ISCUSSION
n our study of MTWA in left ventricular dysfunction,
indeterminate” MTWA tests predicted mortality or SVA
igure 3. Kaplan-Meier estimates of death or non-fatal sustained ventric-
lar arrhythmia at 2 years of follow-up, comparing subgroups of patients
ith indeterminate MTWA results and those with positive MTWA
esults. The 2-year outcome rates were (bottom to top): noise or rapid HR
ise 0.0%, positive MTWA test 12.3%, HR 105 beats/min 14.2%,
nsustained MTWA 21.8%, and excessive ventricular ectopy during
xercise 27.2%. Abbreviations as in Figure 2.t least as well as positive tests. Ninety-four percent of tests plassified as indeterminate by the Cambridge Heart D10
omputer algorithm were judged by 2 expert readers to be
ndeterminate owing to patient factors, and these patients
ad a prognosis as poor as patients with positive tests. The
rincipal clinical utility of MTWA testing lies in its ability
o identify, among patients with left ventricular dysfunction
nd eligible for ICD prophylaxis, a subgroup at low risk
f mortality or SVA. Our findings suggest that both
positive” and “indeterminate” MTWA test results indi-
ate high risk and only patients with a negative MTWA
est are low risk and therefore unlikely to benefit from
CD prophylaxis.
ndeterminate tests due to technical factors. Some inves-
igators have argued against attributing prognostic value to
hese “technically inadequate” indeterminate MTWA tests,
ecause noise does not reflect a physiologically significant
isk factor (15). Although our results support that view, only
% of our tests were judged indeterminate owing to noise or
apid HR rise. Repeating such “technically inadequate”
ndeterminate MTWA tests will result in a positive or
egative test in about one-half of such cases, leaving very
ew tests that cannot be used to risk-stratify for ICD
rophylaxis (12). To obtain a technically adequate MTWA
est requires careful skin preparation and special electrodes
o minimize noise and a HR-guided exercise protocol to
revent a too-rapid rise in HR (8,21,22).
High-risk” indeterminate tests due to patient factors. Of
he 3 patient factors that cause MTWA exercise tests to be
ndeterminate, 2 of them—high levels of ventricular ectopy
nd failure to achieve an adequate HR—were previously
eported to predict poor outcome (23–29). In contrast, the
evelopment of unsustained MTWA at HR 110 beats/
in was not reported previously as a marker of poor
rognosis, but our results suggest that it is. An exercise test
ith MTWA analysis can not only provide valuable prog-
ostic information of MTWA itself but also can reveal
dditional risk predictors such as exercise-induced ventric-
lar ectopy and diminished HR response to light exercise.
revious studies. In 2001, Tapanainen et al. (14) at Oulu
niversity Hospital in Finland first reported that indeter-
inate MTWA tests predicted cardiac death in the 2 years
fter acute MI. A cohort of 379 consecutive patients was
ecruited in-hospital 7 or fewer days after acute MI. Ther-
py in this study was notable for lack of any revasculariza-
ion (patients who had coronary artery bypass graft surgery
ere excluded); 97% were taking beta blocking drugs, and
6% took angiotensin-converting enzyme (ACE) inhibitors
r angiotensin receptor blocker (ARB) medication. MTWA
ests were done 8  2.4 days after the MI; the test results
ere: negative 38%, positive 15%, and indeterminate/
ncomplete 47%. Of 9 risk predictors measured in the
innish study, indeterminate MTWA tests had the stron-
est association with all-cause (primary end point) or
ardiac (secondary end point) death during a mean follow
p of 14  8 months. The MTWA tests had a negative
redictive accuracy of 99%. The authors speculated on
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October 3, 2006:1399–404 Indeterminate T-Wave Alternans Testossible reasons for the very high prevalence of indetermi-
ate/incomplete MTWA tests, primarily the short interval
fter MI or the high frequency of beta blockers and ACE
nhibitors or ARB medication. The MTWA test might
ave been done before the myocardial scar fully “matured”
r before left ventricular remodeling completed. Alterna-
ively, drug therapy, especially beta blockers, might have
ontributed to the large proportion of patients who did not
chieve the target HR of 105 beats/min (30). Patient
ebility or investigator caution also might have contributed
o the inadequate HR rise during exercise testing so soon
fter MI.
The other large post-MI study was conducted at 7
apanese university hospitals and recruited 850 patients (31).
herapy was strikingly different from the Finnish study;
0% of the patients were revascularized, and only 13% were
reated with beta blocking drugs; 18% had a LVEF 0.40.
he MTWA tests were done an average of about 80 days
2.7  5.4 months) after the qualifying MI; the test results
ere: negative 52%, positive 36%, and indeterminate/
ncomplete 12%. Of 11 risk predictors measured in the
apanese study, MTWA had the strongest association with
rrhythmic events (sudden cardiac death, non-fatal ventric-
lar fibrillation or tachycardia) during 25  13 months of
ollow up. A negative MTWA test had a negative predictive
ccuracy of 99%. Of 11 risk predictors, only MTWA and
VEF 0.40 were independently associated with arrhyth-
ic events. Joint use of these 2 risk predictors improved risk
tratification results. Comparing their positive predictive
ccuracy with that in the Finnish study, the Japanese
nvestigators attributed the difference to performing the
TWA test too soon after MI. But, the striking differences
n beta blocker use might also contribute to the differences
n the test performance. Questions remain about the utility
f MTWA early after MI just as questions remain about the
pparent lack of ICD benefit at this stage of MI (32).
In contrast to the 2 large post-MI studies, all of the
atients in our study had chronic left ventricular dysfunction
ith LVEF 0.41, about one-half with ischemic and
ne-half with nonischemic cardiomyopathy. The 49% of
ur patients with ischemic heart disease were enrolled as
utpatients an average of 5 years after acute MI, and the
1% who had nonischemic cardiomyopathy also had long-
tanding left ventricular dysfunction. We had 81% of our
articipants taking beta blockers and 87% taking ACE
nhibitors or ARB medication. Nevertheless, MTWA had
ood positive predictive accuracy and outstanding negative
redictive accuracy (97.5%) during 20 6 months of follow
p. Excellent predictive accuracy in a group of patients, 81%
f whom were taking beta blockers, suggests that the major
ifferences between the Finnish and Japanese studies are
redominantly due to the time after MI that the MTWA
ests were done, with beta blocker treatment being less
mportant. Reduced positive predictive accuracy forTWA tests done in the first 2 weeks does not pose a eroblem for the clinical utility of MTWA. Microvolt
-wave alternans is currently used primarily to identify,
mong patients who have a MADIT-II (3) or SCD HeFT
Sudden Cardiac Death in Heart Failure Trial) (33) indi-
ation for ICD prophylaxis, a low-risk subgroup that is
nlikely to benefit from an ICD implant. Given the results
f DINAMIT (Defibrillator in Acute Myocardial Infarction
rial) (32), there is no imperative to risk stratify post-MI
atients during the first 40 days after MI. Also the negative
redictive accuracy of MTWA tests is 99% even in the 1st
eek after MI.
TWA testing in a clinical setting. In a 2005 meta-analysis
f MTWA, Gehi et al. (15) noted that “[w]hether . . . an
ndeterminate MTWA assessment should be considered ab-
ormal or excluded altogether remains a methodological issue.”
ohnloser et al. (6) studied 129 MADIT-II–like patients
nd found that both indeterminate and positive MTWA
ests identified patients at high risk of arrhythmic events,
hereas patients with negative MTWA tests were at low
isk and therefore unlikely to benefit from ICD prophylaxis.
ur 549-patient study strongly supports Hohnloser’s rec-
mmendation that, on the basis of their association with
ubstantially increased risk, indeterminate MTWA tests be
rouped with positive tests in a single “not negative” or
abnormal” category, for the purpose of clinical decision-
aking and for use in epidemiologic studies or clinical trials.
his clarification of how to manage patients with indeter-
inate MTWA tests presents clinicians with another con-
enience in identifying patients who are likely or unlikely to
enefit from ICD prophylaxis. Our study also showed that
TWA test interpretations made by the Cambridge Heart
10 computer algorithm with no physician over-read
ad excellent predictive accuracy and that patients can
ontinue their chronic medications, including beta block-
rs, during MTWA testing without compromising its
iagnostic accuracy.
onclusions. In patients with left ventricular dysfunction,
n “indeterminate” MTWA test due to ventricular ectopy,
nsustained MTWA, or low HR predicted death or SVA as
ell as a positive test. Conversely, a negative MTWA result
as associated with a very low risk of death or SVA. These
ndings indicate that it is appropriate to combine “indeter-
inate” with positive MTWA results, yielding a single,
igh-risk “abnormal” group and a very low-risk normal
roup. In the clinical setting, this will refine the process of
dentifying patients likely or unlikely to benefit from ICD
rophylaxis and will help doctors and patients to make more
nformed decisions about ICD prophylaxis.
eprint requests and correspondence: Dr. Elizabeth S. Kauf-
an, Heart and Vascular Research Center, Hamann 3rd Floor,
etroHealth Campus, Case Western Reserve University, 2500
etroHealth Drive, Cleveland, Ohio 44109-1998. E-mail:kaufman@metrohealth.org.
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